FIELD: radiopharmaceuticals.
SUBSTANCE: invention relates to compounds that can be used as radiopharmaceuticals and radioimaging agents. The following is proposed: a compound of formula (I) or its pharmaceutically acceptable salt or isomer:
(I)
where: X is C1-C6 alkyl or a group
;
Y is an unsubstituted C1-C12 alkylene group; m is either 0, 1 or 2; and n is either 0, 1, or 2; where the connection is coordinated with a metal ion, where the metal ion is selected from the group consisting of 60Cu, 61Cu, 62Cu, 64Cu and 67Cu. Also the following is proposed: individual compounds (options), a composition for radio imaging and a method of radio imaging of a subject.
EFFECT: proposed compounds are useful in radiotherapy and diagnostic imaging.
15 cl, 11 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
| PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | 2018 |
|
RU2807076C2 |
| NEUROTENSIN RECEPTOR LIGANDS | 2013 |
|
RU2671970C2 |
| PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
| NEW INHIBITOR BASED ON A QUINOLINE DERIVATIVE | 2019 |
|
RU2802283C2 |
| TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS FOR USING THEM FOR PSMA INHIBITION | 2009 |
|
RU2532912C2 |
| DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | 2016 |
|
RU2748992C2 |
| COMPLEX CONTAINING A PSMA-TARGETING COMPOUND BOUND TO A LEAD OR THORIUM RADIONUCLIDE | 2018 |
|
RU2795398C2 |
| CANCER TREATMENT METHODS | 2019 |
|
RU2811406C2 |
| A CONJUGATE CONTAINING A NEUROTENSIN RECEPTOR LIGAND AND ITS APPLICATION | 2015 |
|
RU2743781C2 |
